Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
Widely access to interferon-free direct-acting antiviral regimens (IFN-free DAA) is poised to dramatically change the impact of the HCV epidemic among people who inject drugs (PWID). We evaluated the long-term effect of increasing HCV testing, treatment and engagement into harm-reduction activities,...
Main Authors: | Viviane D Lima, Ignacio Rozada, Jason Grebely, Mark Hull, Lillian Lourenco, Bohdan Nosyk, Mel Krajden, Eric Yoshida, Evan Wood, Julio S G Montaner |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4669174?pdf=render |
Similar Items
-
Hepatic decompensation associated with an interferon-free antiviral therapy in patients with HCV-cirrhosis
by: S N Batskikh, et al.
Published: (2018-11-01) -
Pulmonary vasculitis as a clinical mask of HCV infection: Efficiency of interferon-free antiviral therapy
by: V V Stel'makh, et al.
Published: (2014-11-01) -
The evolving landscape of the economics of HIV treatment and prevention.
by: Bohdan Nosyk, et al.
Published: (2012-02-01) -
Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon.
by: Claudia Mascia, et al.
Published: (2017-01-01) -
Sarcoidosis during HCV antiviral therapy
by: Emanuela De Santis, et al.
Published: (2014-08-01)